- The enterprise features of this platform enable the collection of all advisory board data sets from multiple activities, countries and stakeholder groups which helps identify and act on new insights more efficiently and effectively.
- Virtual Science’s medically-tuned AI features deliver qualitative and quantitative actionable insights and analytics regarding advisory board interactive activities.
- The AI application removes the need for costly and time-consuming medical report writing.
- This platform is enterprise-scalable and designed to empower global and local teams, ensuring thousands of colleagues across companies can quickly share knowledge and drive action, bringing treatment to patients faster.
LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- Headquartered in London and with operations in Europe and North America, Virtual Science creates cutting-edge software as a service (SaaS) in the life-science and healthcare sectors.
Tom Hughes, the CEO of Virtual Science outlines the impact that the AI platform is already having:
“We’ve developed a revolutionary approach to advisory board processes to help organizations move faster at scale, to make decisions that bring their treatments to patients that need them. This process can be continuous, and our medically tuned AI platform replaces the need for dependencies on complex medical writing to create an advisory board report.”
“It is a very exciting time for Virtual Science as we are working with world-leading pharmaceutical organizations. Senior leaders are seeing this approach as a smart way to speed up organizational decision-making, to get ahead of the competition.”
Chih Han Chen, Chief Technology Officer of Virtual Science and longtime expert in the field of AI, added:
“We have medically trained our AI platform to comprehensively capture and analyze healthcare stakeholder interactions. It is the first time that this technology has been used in the scientific advisory board setting, leading to smarter, faster enterprise-wide decision-making.”
Gathering healthcare stakeholder insights is often time-consuming, requiring a lot of deliberations and consultations. However, Virtual Science is working to help clients in the sector to enhance the process, ensuring a more seamless and faster process without compromising the quality of the decision or output.
These solutions equip life science teams to have compliant interactions with healthcare professionals, patient communities and decision-makers in a virtual environment that improves strategic decision-making.
For further information about Virtual Science visit: www.virtualscienceai.com.
About Virtual Science
Virtual Science is a global provider of external stakeholder interaction services in the pharmaceutical field, such as Advisory Boards. The company leverages its virtual platform and AI models to effectively enhance the engagement with stakeholders in R&D, Medical Affairs, Public Affairs, Pricing & Access, and Commercial life science and healthcare company functions.
Media Contact
Virtual Science
Andrew Donlon, Global Marketing Lead
United Kingdom, London
+44 (0)7919 172226
Andrew.donlon@virtualscienceai.com
www.virtualscienceai.com
